Stem cell transplantations – Famicord Group own experience

Home/2013, Vol. 1, No. 1/Stem cell transplantations – Famicord Group own experience

Cell and Organ Transplantology. 2013; 1(1):35-38.
DOI: 10.22494/COT.V1I1.43

Stem cell transplantations – Famicord Group own experience

Gladysz D.1, Pawelec K.1,2, Baran J.1, Boruczkowski D.1
1Polish Stem Cell Bank (PBKM), Warsaw, Poland
2Department of Pediatric, Hematology and Oncology, Warsaw Medical University, Poland

The umbilical cord blood is now a renowned source of stem cells that can be used for hematopoietic stem cell transplantation. Because of cord blood advantages, including immediate availability and higher degree of acceptable HLA mismatch, the number of patients who received such treatment is constantly growing. The limitations of cord blood usage still exist, however laboratory and clinical trials all over the world try to overcome that barriers. Owing to international cooperation of stem cell banks, umbilical cord-derived stem cells from FamiCord Group were used in clinical trials of hematopoietic stem cell transplantations. Ten transplantations, including one autologous, took place in Poland, while the other three were carried out in Hungary. The most common indication was acute leukemia, however among children with hematologic diseases there were also patients with histiocytosis, chronic granulomatous disease or hypoxic ischaemic encephalopathy. Currently many scientists explore the possibilities of umbilical cord stem cell potential clinical usage with promising results.

Full Text PDF

1. Locatelli F. Improving cord blood transplantation in children. Br. J. Haematol. 2009; 147(2):217-26.
2. Rocha V, Wagner JJr, Sobocinski K, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med. 2000; 342(25):1846-54.
3. Rocha V., Broxmeyer H. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16(1 Suppl):126-32.
4. Sideri A, Neokleous N, Brunet De La Grange P, et al. An overview of the process on double umbilical cord blood transplantation. Haematologica. 2011; 96:1213-20.
PMid:21546497 PMCid:PMC3148916
5. Broxmeyer H. Effect of CD26 on cord blood, and other means to enhance engraftment of hematopoietic stem cells. Biology of Blood and Marrow Transplantation. 2007; 13:1394-95.
6. Ratajczak M, Reca R, Wysoczynski M, et al. Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia. 2004; 18:1482-90.
7. von Drygalski A, Savatski L, Eastwood D, et al. The rate of marrow recovery and extent of donor engraftment following transplantation of ex vivo-expanded bone marrow cells are independently influenced by the cytokines used for expansion. Stem Cells Dev. 2005; 14:564-75.
8. Ramirez P, Wagner J, Brunstein C. Going straight to the point: intra-BM injection of hematopoietic progenitors. Bone Marrow Transplant. 2010; 45:1127-33.
9. De Lima M, Robinson S, McMannis J, et al. Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. ASH Ann. Meeting Abstracts. 2010; 116:362.
10. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat. Med. 2010; 16:232–36.
PMid:20081862 PMCid:PMC2819359
11. Taupin P. Ex vivo fucosylation to improve the engraftment capability and therapeutic potential of human cord blood stem cells. Drug Discov. Today. 2010; 15:698-99.
12. Farag S, Srivastava S, Messina-Graham S, et al. In Vivo DPP-4 Inhibition to Enhance Engraftment of Single-Unit Cord Blood Transplants in Adults with Hematological Malignancies. Stem Cells Dev. 2013; 22:1007-15.
PMid:23270493 PMCid:PMC3607909
13. Broxmeyer H, Lee M, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011; 117(18):4773-7.
PMid:21393480 PMCid:PMC3100689
14. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Va Med Mon. – 1972; 99(3):276-80.
15. Gluckman E, Broxmeyer H, Auerbach A, et al. Haematopoietic reconstitution in a patient with Fanconi’s anaemia by means of umbilical cord blood from an HLA identical sibling. N Engl J Med. – 1989; 321(17):1174-78.
16. Kurtzberg J, Graham M, Casey J, et al. The use of umbilical cord blood in mismatched and unrelated hemopoietic stem cell transplantation. Blood Cells. 1994; 20(2-3):275-83.
17. Ferreira E, Pasternak J, Bacal N, et al. Autologous cord blood transplantation. Bone Marrow Transplant. 1999; 24(9):1041.
18. Schmitz N, Gratwohl A, Goldman J. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow Transplant. 1996; 17(4):471-77.
19. Goldman J, Schmitz N, Niethammer D, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998; 21(1):1-7.
20. Urbano-Ispizua A, Schmitz N, de Witte T, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions, current practice in Europe. Bone Marrow Transplant. 2002; 29(8):639-46.
21. Ljungman P, Urbano-Ispizua A, Cavazzano-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definition and current practice in Europe. Bone Marrow Transplant. 2006; 37(5):439-49.
22. Gratwohl A, Baldomero H. European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications. Transfus. Apher. Sci. 2010; 42(3):265-75.
23. Eurocord Registry – Agence de la Biomédecine, UPDATE, WDMA – CBWG, May 2012. Eurocord Registry at ABM. General data base overview –, (15.08./2013).
24. Boruczkowski D., Kałwak K., Chybicka A. The first cord blood transplantation from commercial cord blood bank in Poland. In: International Conference “Stem cell and cell therapy”. Abstracts and Presentation. 2 Nov. 2007; Riga, Latvia.
25. Boruczkowski D., Sabliński J., Ołdak T. et al. Pierwsze w Polsce transplantacje krwi pępowinowej z komercyjnego banku – opis dwóch przypadków. Onkologia Polska. 2008; 11(supl. 1):74.
26. Janowski M, Kmieć T, Jurkiewicz E, et al. Umbilical Cord Blond-derivates for treatment of globar cerebral ischemic injury in one year old child – a case study. In: Abstract Book of 39th Congress of the Polish Society of Neurosurgeons and the Nursing Section with the participation of the Hellenic Neurosurgical Society. 17-20 Sept. 2009; Mikołajki, Poland.
27. Boruczkowski D, Sabliński J, Ołdak T, et al. Pierwsze w Polsce transplantacje krwi pępowinowej z komercyjnego banku – opis trzech przypadków. Przegląd Pediatryczny. 2009; 39(supl. 1):123.
28. Brunstein C. Umbilical cord blood transplantation for the treatment of hematologic malignancies. Cancer Control. 2011; 18(4):222-36.
29. Goussetis E, Peristeri J, Kitra V, et al. Combined umbilical cord blood and bone marrow transplantation in the treatment of beta-thalassemia major. Pediatr Hematol Oncol. 2000. 17(4):307-14.
30. Tracey A, et al. Directed Donor Umbilical Cord Blood: Assessment of Banking Practices and Transplant Outcomes. Blood. 2003; 102(11):Abstract #5594.
31. Klein M, Kadidlo D, McCullough J, et al. Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae. Biol Blood Marrow Transplant. 2006. 12(11):1142-49.
32. Kamble R, Pant S, Selby G, et al. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion. 2005; 45(6):874-8.
33. Kelly M, Roy D, Labbe A, et al. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria?. Bone Marrow Transplant. 2006; 38(3):183-8.
34. A service of the U.S. National Institutes of Health, (21.08.2013).
35. Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009; 23(5):199-204.
36. Liuba K, Pronk C, Stott S, et al. Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors. Blood. 2009; 113(19):4790-98.

Gladysz D, Pawelec K, Baran J, Boruczkowski D. Stem cell transplantations – Famicord Group own experience. Cell and Organ Transplantology. 2013; 1(1):35-38. doi: 10.22494/COT.V1I1.43


Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.